Grant ID RP170399
Awarded On November 16, 2016
Title Elimination of hypoxia sensitizes resistant solid tumors to immunotherapy
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Michael Curran
Cancer Sites Prostate
Contracted Amount $899,993
Lay Summary

Unfortunately, as they form, cancers evolve means to hide from and locally dampen the immune system allowing them to thrive when they would otherwise be eliminated. In melanoma, we have shown that by blocking key molecules which cancers engage to shut off the immune system, even bulky metastatic tumors can be immunologically rejected. Unlike most therapies for solid tumors, immunotherapy has the potential to effectively cure a patient of all cancer and ward against its return. Despite these dramatic responses in some cancers, metastatic solid tumors such as prostate cancer respond poorly to immunotherapy. Discovering the mechanisms driving the immunotherapy resistance of these tumors an...

Read More